Overview

Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS

Status:
Recruiting
Trial end date:
2022-08-07
Target enrollment:
Participant gender:
Summary
This multi-center, open, randomized study will evaluate the efficacy and safety of BDB-001 injection in severe COVID-19 with severe pneumonia, or acute lung injury/acute respiratory distress syndrome. Patients will be randomized to two treatment arms (Arm A: Conventional treatment + BDB-001; Arm B: Conventional treatment alone).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Collaborator:
Beijing Defengrui Biotechnology Co. Ltd